# FDA 483 - Corixa Corporation d.b.a. GlaxoSmithKline - March 04, 2022

Source: https://www.globalkeysolutions.net/records/483/corixa-corporation-dba-glaxosmithkline/66b7f6dc-5234-4cb2-9241-fd571a6609fb

> FDA 483 for Corixa Corporation d.b.a. GlaxoSmithKline on March 04, 2022. Product: drugs. Access full analysis and detailed observations.

---

## Details

- Record Type: 483
- Company Name: Corixa Corporation d.b.a. GlaxoSmithKline
- Inspection Date: 2022-03-04
- Product Type: drugs
- Office Name: Division of Clinical Evidence and Analysis 1 (Clinical Policy and Quality)

## Related Officers

- [FDA Biologics Investigator](https://www.globalkeysolutions.net/people/viviana-matta/6fecf0ca-0edc-4538-a57e-72642f41b5c7)
- [Pankaj Amin, CSO](https://www.globalkeysolutions.net/people/pankaj-amin-cso/d01a4c72-08cd-409e-99bc-3e54afcbd17a)
- [Investigator](https://www.globalkeysolutions.net/people/burnell-m-henry/dece4407-3597-4a58-8756-5abf9db43bbc)

Company: https://www.globalkeysolutions.net/companies/corixa-corporation-dba-glaxosmithkline/073e79ff-24d9-475f-980f-49be864eeef8

Office: https://www.globalkeysolutions.net/offices/division-of-clinical-evidence-and-analysis-1-clinical-policy-and-quality/5f95da17-30bb-423f-b892-5ea041823fbd